---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-245701"
form_type: "8-K"
ticker: "INTI"
cik: "0001042418"
company_name: "Inhibitor Therapeutics, Inc."
filed_at: "2022-09-15T23:59:59+00:00"
generated_at: "2026-06-23T09:17:44.676855+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Inhibitor Therapeutics settles derivative/class actions; Mayne to pay $14.25M cash and surrender equity

## Summary
- Mayne to pay $14.25M cash and surrender all its equity (205M+ common shares, convertible preferred, warrants); Mayne debt of $3M canceled.
- Individual defendants Brendan Magrab, Stefan Cross, R. Dana Ono, et al. to retire from board/management; their options/warrants canceled.
- Third Amended Supply and License Agreement with Mayne canceled; Company retains royalty on future US SUBA-Itraconazole BCCNS sales.
- Company's hedgehog-related patents to Mayne become non-exclusive; Mayne's itraconazole formulation patents licensed to Company are terminated.
- Settlement hearing set for November 10, 2022 in Delaware Chancery Court; plaintiffs may seek up to $2M in fees from the cash consideration.

## SEC filing metadata
- accession: 0001193125-22-245701
- form_type: 8-K
- ticker: INTI
- cik: 0001042418
- company_name: Inhibitor Therapeutics, Inc.
- filed_at: 2022-09-15T23:59:59+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1042418/000119312522245701/0001193125-22-245701-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1042418/000119312522245701/d120799d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-245701
- JSON: https://secwatch.observer/filing/0001193125-22-245701.json
- Plain text: https://secwatch.observer/filing/0001193125-22-245701.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.